国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2013年
21期
3257-3260
,共4页
复发性鼻咽癌%尼妥珠单抗%三维适形放疗%顺铂
複髮性鼻嚥癌%尼妥珠單抗%三維適形放療%順鉑
복발성비인암%니타주단항%삼유괄형방료%순박
Recurrent nasopharyngeal carcinoma%Nimotuzumab%Three dimensional conformal radiotherapy%Cisplatin
目的 观察尼妥珠单抗联合三维适形放疗对复发性鼻咽癌的疗效和不良反应.方法 32例符合入选标准的复发性鼻咽癌患者按照随机的方法分为两组,对照组采用顺铂方案联合三维适形放射治疗,放疗剂量为60～70Gy/6-7W,2Gy/次,5次/W.在放疗期间予顺铂(20 mg/m2d 1-4)同期全身化疗2个疗程,每3周为一疗程.实验组采用尼妥珠单抗联合三维适形放疗,放疗第一天开始用尼妥珠单抗100 mg加生理盐水250 ml静脉滴注,输液时间不少于60分钟,每周1次,共6～7次.结果 16例接受三维适形放疗联合顺铂化疗的复发性鼻咽癌患者治疗结束后的有效率为43.75％,控制率为68.75％; 16例接受尼妥珠单抗联合三维适形放疗的复发性鼻咽癌患者治疗结束后的有效率和控制率分别为50％和75％,两组间差异无统计学意义.相关的不良反应中,尼妥珠单抗组骨髓抑制及消化道反应发生率较低,两组间差异有统计学意义.与尼妥珠单抗相关的不良反应主要是发热(25％)、血压下降(18.75％)、皮疹(18.75％),以上不良反应均未影响治疗进程.结论 尼妥珠单抗联合三维适形放疗对于复发性鼻咽癌患者有较好的疗效,不良反应的发生率较低,是复发性鼻咽癌有效的治疗手段.
目的 觀察尼妥珠單抗聯閤三維適形放療對複髮性鼻嚥癌的療效和不良反應.方法 32例符閤入選標準的複髮性鼻嚥癌患者按照隨機的方法分為兩組,對照組採用順鉑方案聯閤三維適形放射治療,放療劑量為60～70Gy/6-7W,2Gy/次,5次/W.在放療期間予順鉑(20 mg/m2d 1-4)同期全身化療2箇療程,每3週為一療程.實驗組採用尼妥珠單抗聯閤三維適形放療,放療第一天開始用尼妥珠單抗100 mg加生理鹽水250 ml靜脈滴註,輸液時間不少于60分鐘,每週1次,共6～7次.結果 16例接受三維適形放療聯閤順鉑化療的複髮性鼻嚥癌患者治療結束後的有效率為43.75％,控製率為68.75％; 16例接受尼妥珠單抗聯閤三維適形放療的複髮性鼻嚥癌患者治療結束後的有效率和控製率分彆為50％和75％,兩組間差異無統計學意義.相關的不良反應中,尼妥珠單抗組骨髓抑製及消化道反應髮生率較低,兩組間差異有統計學意義.與尼妥珠單抗相關的不良反應主要是髮熱(25％)、血壓下降(18.75％)、皮疹(18.75％),以上不良反應均未影響治療進程.結論 尼妥珠單抗聯閤三維適形放療對于複髮性鼻嚥癌患者有較好的療效,不良反應的髮生率較低,是複髮性鼻嚥癌有效的治療手段.
목적 관찰니타주단항연합삼유괄형방료대복발성비인암적료효화불량반응.방법 32례부합입선표준적복발성비인암환자안조수궤적방법분위량조,대조조채용순박방안연합삼유괄형방사치료,방료제량위60～70Gy/6-7W,2Gy/차,5차/W.재방료기간여순박(20 mg/m2d 1-4)동기전신화료2개료정,매3주위일료정.실험조채용니타주단항연합삼유괄형방료,방료제일천개시용니타주단항100 mg가생리염수250 ml정맥적주,수액시간불소우60분종,매주1차,공6～7차.결과 16례접수삼유괄형방료연합순박화료적복발성비인암환자치료결속후적유효솔위43.75％,공제솔위68.75％; 16례접수니타주단항연합삼유괄형방료적복발성비인암환자치료결속후적유효솔화공제솔분별위50％화75％,량조간차이무통계학의의.상관적불량반응중,니타주단항조골수억제급소화도반응발생솔교저,량조간차이유통계학의의.여니타주단항상관적불량반응주요시발열(25％)、혈압하강(18.75％)、피진(18.75％),이상불량반응균미영향치료진정.결론 니타주단항연합삼유괄형방료대우복발성비인암환자유교호적료효,불량반응적발생솔교저,시복발성비인암유효적치료수단.
Objective To investigate efficacy and tolerability of nimotuzumab in combination with three dimensional conformal radiotherapy in recurrent nasopharyngeal carcinoma.Methods 32 cases of recurrent nasopharyngeal carcinoma were randomly divided into control group and experimental group,16 cases in each group.Control group was treated with conventional concomitant fractionated radiation (60-70 Gy in 2 Gy fractions) and 2 cycles of cisplatin 20 mg/m2 (d1-4) every 3 weeks.Nimotuzumab was added at a dose of 100 mg i.v.weekly for 6-7 weeks at the beginning of radiotherapy in experimental group.Results The response rate (RR) and the disease control rate (DCR) of control group were 43.75％ and 68.75％ respectively,while those of experimental group were 50％ and 75％ respectively,without significant differences between two groups.The most common reported adverse events were lymphopenia and gastrointestinal reactions,with significant difference between two groups.The most frequent nimotuzumab-related adverse events were fever (25％),hypotension (18.75％) and rash (18.75％),which didn' t disturb the therapy.Conclusion Nimotuzumab in combination with three dimensional conformal radiotherapy is well-tolerated and feasible for recurrent nasopharyngeal carcinoma,worthy of clinical application.
